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Abstract
Background: The burden, clinical features, and molecular epidemiology of norovirus infection in young children in
southern Africa are not well defined.
Methods: Using data from a health facility-based surveillance study of children <5 years in Lusaka Province, Zambia
presenting with diarrhea, we assessed the burden of norovirus infection. A convenience sample of 454 stool specimens
was tested for norovirus using reverse-transcriptase polymerase chain reaction (RT-PCR). RT-PCR positive samples
underwent additional nucleotide sequencing for genogroup and genotype identification. Clinical features and
severity of diarrheal illnesses were compared between norovirus-positive and -negative subjects using Chi-squared
and t-tests.
Results: Norovirus was detected in 52/454 (11.5%) specimens tested. Abdominal pain, fever, and vomiting were the
most common presenting features in norovirus-associated illnesses. However, there were no significant differences in
the clinical features of norovirus-positive compared to norovirus-negative illnesses. Of 43 isolates that were available for
sequencing, 31 (72.1%) were genogroup II (GII) and 12 (27.9%) were genogroup I (GI). The distribution of genotypes
was diverse.
Conclusions: Noroviruses were detected in approximately 10% of young children with diarrhea in the Lusaka
Province of Zambia, with GII representing the majority of infections. These findings support the role of norovirus
in symptomatic diarrhea disease in Africa. Further studies are needed to confirm these observations and to evaluate
prevention strategies.
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Background
Norovirus (NoV) is a common cause of acute gastro-
enteritis (AGE) worldwide. NoVs are members of the
Caliciviridae family and are divided into six genogroups,
of which genogroups I and II (GI and GII) are respon-
sible for the majority of human disease [1, 2]. Each gen-
ogroup can be further distinguished into genotypes, with
GI and GII comprised of at least 9 and 22 genotypes,
respectively [2]. Most human NoV infections are caused
by GII strains, and a single genotype, GII.4, is respon-
sible for approximately 55–85% of clinical cases world-
wide [2].
NoV is the most common cause of acute gastroenteritis
in outbreak settings [3]. However, NoV is also a leading
cause of AGE among children in the community. Since
the introduction of rotavirus vaccines, NoV has replaced
rotavirus as the leading cause of medically attended AGE
in children < 5 years of age in the United States [4, 5].
However, the burden of norovirus-associated diarrheal in-
fections in the pre- and post-rotavirus vaccination era has
not been fully characterized in other regions, including
southern Africa. We aimed to evaluate the prevalence,
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clinical features, and molecular epidemiology of NoV in-
fections in children < 5 years of age in Zambia, a country
that implemented infant rotavirus vaccination in 2013,
using data from a health facility-based surveillance study.
Methods
Study setting
The study was conducted in six health facilities through-
out the Lusaka Province of Zambia. Three facilities were
in Lusaka District, the most densely populated urban
district in Zambia and three additional facilities were
located in each of the three remaining districts, Kafue,
Chongwe and Luangwa, which contain a lower density,
more rural population. In January 2012 the Zambian
Government, in partnership with the Centre for Infec-
tious Disease Research in Zambia (CIDRZ) and Absolute
Return for Kids (Ark, a United Kingdom-based chil-
dren’s charity), initiated a 2-year, pilot introduction of
the Rotarix® live, oral rotavirus vaccine in public health
facilities in Lusaka Province [6, 7]. Following this suc-
cessful pilot, the vaccine was nationally implemented
into the Expanded Programme on Immunisations (EPI)
in November 2013. Facilities that met specific criteria
were purposefully selected as study sites, including (i)
sufficient numbers of patients under 5 years, (ii) space to
support study activities, (iii) and participation in the
pilot vaccine roll-out.
Study design
From July 2012 to October 2013, active health facility-
based surveillance was conducted among the six sentinel
health facilities to identify and enroll children less than
5 years of age with diarrheal illnesses. Children were
considered eligible if they met the following criteria: age
0–59 months; admitted to the inpatient department
(IPD) or under care in the outpatient department (OPD)
at the time of screening; and verbal confirmation by the
caregiver that the child passed three or more abnormally
loose stools in the past 24 h. Eligibility criteria also in-
cluding having signs of potentially severe diarrhea by
confirmation of at least one of the following symptoms
assessed through physical examination by the study nurse
or verbal confirmation by the caregiver: sunken eyes, loss
of normal skin turgor, intravenous rehydration prescribed/
administered, blood in stool, and hospitalization for diar-
rhea or dysentery. Inclusion criteria also included pres-
ence of a caregiver who could provide written informed
consent and who was willing to have study procedures
carried out on the eligible child. Subjects who had pre-
viously participated in the study within the last 30 days
were excluded.
After providing written informed consent, caregivers
of participants were interviewed at enrollment to collect
detailed information regarding individual and household
demographics, symptoms associated with the child’s
present illness, and the child’s health background. The
child’s vaccination history and growth trajectory were also
recorded from the child health record, when available, or
by verbal report by caregiver when not. If the child was
admitted to the health facility, time-to-discharge and other
features of illness were collected. A home visit was also
conducted 30 days after enrollment or discharge from the
facility to determine the child’s vital status.
Stool sample collection and handling
Study staff asked the child’s caregiver to be notified
when the child indicated a need to use the toilet or after
the child had produced stool in the diaper. Approxi-
mately 10–15 mL of bulk stool was collected from each
child at enrollment. Stool specimens were collected in
sterile specimen containers, refrigerated immediately
after collection, and transported from the study sites to
the CIDRZ laboratory in Lusaka.
Laboratory procedures
All stool samples collected were initially screened for
rotavirus antigen by enzyme immunoassay (EIA) using a
monoclonal antibody solid phase sandwich as part of a
larger assessment of rotavirus vaccine effectiveness [8].
The Meridian Rotaclone EIA kit for the detection of
rotavirus antigen in fecal samples (CAT No. 696004)
was used for the analysis.
Norovirus RNA isolation and detection
A convenience sample of available stool specimens was
processed to undergo norovirus testing by reverse-
transcriptase polymerase chain reaction (RT-PCR). RNA
was extracted from 140 μL of fecal suspension using the
QIAampViral RNA Mini Kit, (Qiagen, Hieden, Germany).
Purified RNA aliquots were stored at −80 C. One step RT-
PCR was performed on the stored samples using the JV12i/
JV13y primers targeting the ORF1 region, which encodes
the RNA-dependent RNA-polymerase gene [9]. The final
volume for each reaction was 25 μL. Each reaction con-
tained 5.0 μL of 5x one step RT-PCR buffer; 1.0 μL of
40 μM dNTPs; 0.5 μL of each primer for (20 μM each);
1 μL of One step RT-PCR Enzyme mix (5 U/μL), 5 μL of
sample RNA, and 11 μL of nuclease-free water. The
amplification conditions were set as follows: Reverse
transcription 42 °C for 30 min, followed by 94 °C for
5 min, then 40 cycles of 94 °C for 30 s, 50 °C for 30 s,
72 °C for 30 s, and an extension step at 72 °C for
10 min. All RT-PCR products were analyzed by 1.5%
agarose gel electrophoresis.
DNA sequencing and genotyping
All positive RT-PCR products were purified using Gene-
JET PCR Kit (Thermo Scientific) and sequenced with
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BigDye Terminator v3.1 cycle sequencing kit using an
ABI 3130 XL Genetic analyzer (Applied Biosystems,
Foster City, CA). Nucleotide sequences were edited with
Sequencer Version 5.0. The partial RNA-dependent
RNA-polymerase genotypes of sequenced isolates were
determined using the Norovirus Genotyping Tool Ver-
sion 1.0 (National Institute for Public Health and the
Environment; Bilthoven, The Netherlands). Phylogen-
etic relationships of the norovirus were analyzed by
aligning sequences from the GenBank database using
clustalw software. Phylogenetic trees of nucleotide se-
quences of the partial RNA-dependent RNA polymer-
ase region of GI or GII isolates were constructed by
the neighbor joining method [10] using MEGA version
5.0 software [11] and validated by 1000 bootstrap repli-
cates [12].
Human subjects protection
The study was approved by research ethics authorities at
the Zambian Ministry of Health, the University of
Zambia, the University of Alabama at Birmingham, and
the University of North Carolina at Chapel Hill. Care-
givers of participants provided written informed consent
prior to initiation of study procedures.
Statistical analysis
The distribution of genogroups among the norovirus
detections sequenced and the seasonality of norovirus
detections were described. To compare the clinical fea-
tures of AGE among norovirus-positive versus norovirus-
negative episodes of diarrheal illness, Chi-squared tests
and t-tests were utilized for categorical or continuous out-
come variables, respectively. Severity scores were calcu-
lated post-hoc for each diarrheal illness for which clinical
data were available using the 20-point Modified Vesikari
score [13–15] and compared among norovirus genogroup
and according to viral detection.
Results
Norovirus prevalence and distribution of genogroups and
genotypes
A total of 1506 subjects were enrolled in the primary
study and provided stool specimens. Rotavirus positivity
among these was 41.2% (621/1506). From 1506 stool
specimens collected during the study, a convenience
sample of 454 (30%) specimens was selected for noro-
virus testing. Overall, 52/454 (11.5%) of these specimens
were positive for norovirus by RT-PCR (Fig. 1). Of 52
norovirus-positive samples, 43 (82.7%) were successfully
Fig. 1 Consort diagram
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sequenced for genogroup characterization. The majority
of these (31/43; 72.1%) were GII, while 12/43 (27.9%)
were GI.
Genotype determination was not possible in 7/43 sam-
ples due to short sequences not supported by MEGA V.5.
In the 36 strains genotyped, there were 9 GI samples and
27 GII samples. Of 9 GI strains successfully genotyped,
strains clustered as follows: 6 GI.P7, 2 GI.P2, and 1 GI.P5
(Additional file 1: Figure S1A). Of 27 GII strains success-
fully genotyped, strains clustered as follows: 19 GII.P4, 4
GII.Pe and 4 GII.P2 (Additional file 1: Figure S1B).
Clinical features of norovirus-positive compared to
norovirus-negative diarrheal illnesses
Detailed clinical and sociodemographic data were avail-
able for 289/454 (63.7%) samples, including 23 of the 52
(44.2%) in which norovirus was detected (Table 1). The
mean duration of diarrhea was 2.9 days in these 23
norovirus-positive diarrheal illnesses; no subjects re-
ported bloody diarrhea. Abdominal pain, fever, and
vomiting were the most common features present dur-
ing norovirus infections, and occurred in 15/23 (68.1%),
10/23 (45.4%), and 9/23 (42.9%) norovirus-positive epi-
sodes, respectively. Rotavirus was co-detected in 6/23
(26%) episodes of norovirus-positive diarrheal illness;
two of these subjects had received one rotavirus vaccine
dose, but none had received two rotavirus vaccine doses.
NoV detections occurred throughout the year, with no
discernible seasonal pattern (Fig. 2). Ten of 23 (43%)
subjects with norovirus infection and clinical data avail-
able had received at least one rotavirus vaccine dose. In
the subjects in whom all data were available to calculate
a Modified Vesikari Score, most (16/19; 84.2%) illnesses
were characterized as mild, and the remainder (3/19;
15.8%) were characterized as moderate. Three of 21
(14.3%) children with norovirus-positive diarrheal illness
were admitted to the health care facility. None of these
children were also rotavirus-positive; length of stay for
each admitted child was 2 days.
The types of household toilet facilities available varied
significantly between those with norovirus-positive com-
pared to norovirus-negative diarrheal illnesses, with pit
latrines with slab bases the most common toilet facility
among children with norovirus-positive episodes. Other-
wise, there were no significant differences in the demo-
graphic or clinical features of norovirus-positive versus
norovirus-negative diarrheal illnesses in those with avail-
able data in our cohort, including rotavirus vaccination
status, duration of diarrhea, duration of fever, presence
of blood in stool, vomiting, abdominal pain, fever, or
rotavirus stool positivity (Table 1). Similarly, there were
no significant differences in the clinical features of noro-
virus infections compared to rotavirus infections (data
not shown). Similarly, when the severity of illness was
compared according to the detection of norovirus or
rotavirus, no significant differences were observed (noro-
virus-positive/rotavirus negative: 10/13 (77%) mild, 3/13
(23%) moderate; rotavirus-positive/norovirus negative: 66/
84 (79%) mild, 18/84 (21%) moderate, norovirus-positive/
rotavirus-positive 6/6 (100%) mild; p = 0.065). Similarly,
no differences were observed in illness severity among GI
compared to GII norovirus infections (Table 2).
Discussion
We present the first report to our knowledge of the rate
of norovirus infections among young children with diar-
rheal illness in Zambia using data obtained from a sys-
tematic surveillance study. The period prevalence of
norovirus in these facilities was 11.5%, compared to 41%
rotavirus period prevalence in this partially vaccinated
population [7]. Diarrheal illness due to NoV is common
among young children in this setting, and may become
more important as rotavirus vaccine uptake increases.
The clinical characteristics of norovirus positive and
negative illnesses were not distinguishable. Several dis-
tinct norovirus genotypes were identified in this popula-
tion, with GII represented in nearly three-quarters of the
norovirus detections.
The recent finding that NoV replaced rotavirus as the
leading etiology of childhood diarrhea after widespread
rotavirus vaccine implementation in the United States
[4] has generated substantial interest in defining the bur-
den of norovirus disease in other regions. Several studies
have examined the prevalence of norovirus detection
among children presenting with diarrheal infections in
sub-Saharan Africa. In the multicenter Global Enteric
Multicenter Study (GEMS), conducted from 2007 to
2011, norovirus did not contribute substantially to mor-
tality in children <5 years presenting to one of seven
field sites in Asia or Africa with moderate-to-severe diar-
rhea [16]. In contrast, a multi-site birth cohort study of
children utilizing prospective community surveillance
conducted at several sites in South America, Asia, and
Africa from 2009 to 2012 (Etiology, Risk Factors, and In-
teractions of Enteric Infections and Malnutrition and the
Consequences for Child Health and Development Pro-
ject; MAL-ED), found that NoV GII infections were
associated with the highest or near-highest attributable
burden of diarrheal illness in the first and second years
of life [17]. Further, they found that 89% of children
experienced at least one norovirus infection before
24 months, with similar disease severity to other entero-
pathogens [18]. The difference in these findings may be
related to study design; while the GEMS study was de-
signed as a case–control study and primarily recruited
from health centers, the prospective birth cohort MAL-
ED study captured household disease. Recent studies
evaluating the prevalence of diarrheal pathogens among
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Table 1 Sociodemographic and clinical features of norovirus-positive compared to norovirus-negative diarrheal illness episodes in
young Zambian children
Norovirus positive (n = 23) Norovirus negative (n = 266) p
Sociodemographic and background characteristics
Sex 0.240
Female 14/22 (63.6) 127/257 (49.4)
Male 8/22 (36.3) 130/257 (50.6)
Age 0.797
< 1 month 0 (0.0) 3/266 (1.1)
1–6 months 2/23 (8.7) 31/266 (11.7)
6–12 months 10/23 (43.5) 106/266 (39.8)
12–24 months 9/23 (39.1) 83/266 (31.2)
> 24 months 2/23 (8.7) 43/266 (16.2)
Number of siblings 0.867
0 8/21 (38.1) 69/210 (32.9)
1 4/21 (19.1) 53/210 (25.2)
2 4/21 (19.1) 48/210 (22.9)
3 2/21 (9.5) 17/210 (8.1)
≥ 4 3/21 (14.3) 23/210 (11.0)
Household electricity 15/23 (65.2) 164/258 (63.6) 0.875
Household drinking water source 0.793
Communal tap 12/19 (63.1) 110/244 (45.1)
Piped to yard 3/19 (15.8) 39/244 (16.0)
Piped into dwelling 2/19 (10.5) 36/244 (14.8)
Protected public well 1/19 (5.3) 21/244 (8.6)
River/stream 0/19 (0.0) 14/244 (5.7)
Other 1/19 (5.3) 24/244 (9.8)
Household livestock 3/23 (13.0) 28/251 (11.2) 0.784
Toilet facility 0.031
Flush/pour flush to piped sewer 1/20 (5.0) 41/225 (18.2)
Flush/pour flush to septic tank 3/20 (15.0) 42/225 (18.7)
Flush/pour flush to pit latrine 3/20 (15.0) 3/225 (1.3)
Improved ventilated pit latrine 1/20 (5.0) 16/225 (7.1)
Pit latrine with slab 10/20 (50.0) 78/225 (34.7)
Open pit latrine without slab 2/20 (10.0) 44/225 (19.6)
Hanging toilet/hanging latrine 0/20 (0.0) 1/225 (0.4)
Child ever diagnosed with HIV/AIDS 0/18 (0.0) 1/201 (0.5) 1.000
Number of rotavirus vaccines received
0 doses or unknown 13/23 (56.5) 171/266 (64.3)
At least 1 dose 10/23 (43.4) 95/266 (35.7) 0.458
2 doses 8/23 (34.8) 79/266 (30.0) 0.610
Clinical features at presentation
Severity score by category 0.766
≤ 10 (mild) 16/19 (84.2) 156/183 (85.3)
11–14 (moderate) 3/19 (15.8) 26/183 (14.2)
≥ 15 (severe) 0/19 (0.0) 1/183 (0.6)
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Table 1 Sociodemographic and clinical features of norovirus-positive compared to norovirus-negative diarrheal illness episodes in
young Zambian children (Continued)
Degree of dehydration on admission 0.319
None 2/23 (8.7) 57/259 (22.0)
Mild 7/23 (30.4) 55/259 (21.2)
Moderate 14/23 (60.9) 136/259 (52.5)
Severe 0/23 (0.0) 11/259 (4.3)
Duration of diarrhea, days 0.505
1–4 21/22 (95.5) 203/221 (91.9)
5 1/22 (4.5) 6/221 (2.7)
≥ 6 0/22 (0.0) 12/221 (5.4)
Max stools/day 0.444
1–3 14/22 (63.6) 112/217 (51.6)
4–5 8/22 (36.4) 90/217 (41.5)
≥ 6 0/22 (0.0) 15/217 (6.9)
Blood in stool 0/22 (0.0) 8/216 (3.7) 1.000
Vomiting 9/21 (42.9) 83/221 (37.1) 0.603
Duration of vomiting, days 0.593
0 12/22 (54.6) 139/221 (62.9)
1 1/22 (4.6) 9/221 (4.1)
2 5/22 (22.7) 49/221 (22.2)
≥ 3 4/22 (18.2) 24/221 (10.9)
Maximum vomiting episodes/day 0.502
0 12/22 (54.6) 139/218 (63.8)
1 0/22 (0.0) 5/218 (2.3)
2–4 10/22 (45.5) 65/218 (29.8)
≥ 5 0/22 (0.0) 9/218 (4.1)
Abdominal pain 15/22 (68.2) 137/205 (66.8) 0.898
Caregiver-reported fever 10/22 (45.5) 97/217 (44.7) 0.946
Maximal recorded temperature, °C 0.877
< 37.0 15/22 (68.2) 172/245 (70.2)
37.1–38.4 7/22 (31.8) 60/245 (24.5)
38.5–38.9 0/22 (0.0) 6/245 (2.5)
≥ 39.0 0/22 (0.0) 7/245 (2.9)
Duration of fever 2.4 (1.2) 2.6 (1.3) 0.605
Decreased energy/malaise 13/21 (61.9) 147/217 (67.7) 0.586
Excessive crying 14/22 (63.6) 96/218 (44.0) 0.079
Admitted to hospital 3/21 (14.3) 32/223 (14.4) 1.000
Rotavirus positive 6/23 (26.1) 104/263 (39.5) 0.203
30 day follow-up
Status of child 1.000
Fully recovered 10/10 (100.0) 120/133 (90.20)
Partially recovered 0/10 (0.0) 6/133 (4.5)
Worsening 0/10 (0.0) 1/133 (0.8)
Recovered but became sick again 0/10 (0.0) 6/133 (4.5)
Bold text indicates statistical significance (p < 0.05)
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children with diarrhea in sub-Saharan Africa have re-
ported NoV prevalence ranging from 9 to 25% among
subjects with diarrhea, with typically 75 to 95% of symp-
tomatic NoV detections associated with detection of NoV
G.II [18–28]. In the studies that also enrolled asymptom-
atic controls, the prevalence of NoV in stool specimens
obtained from asymptomatic subjects ranged from 3.9 to
31% and sometimes exceeded the prevalence in symptom-
atic subjects. However, cycle threshold values as surro-
gates for viral loads were useful in identifying clinically
relevant NoV detections [21, 22]. Additionally, inter-study
comparisons are limited by the use of different NoV
detection methods as well as different definitions of cases
and controls, reducing the generalizability of the two stud-
ies to other settings.
Our study has several important limitations. First, our
surveillance was impaired by uneven collection of data.
Clinical data were collected but were not systematically
recorded in the first five months of the study, represent-
ing 37% of the total stool samples that were tested for
norovirus. Study data collection forms were changed in
November 2012; thus, the clinical features of illnesses
prior to this transition are not captured. Additionally,
stool samples were not collected from a substantial pro-
portion of enrolled subjects (521/2027; 26%). The sam-
ple size of our study and the large number of missing
stool samples are both important limitations, which may
impact the generalizability of our results. In addition,
our use of a convenience sample, rather than a random
sample, may have introduced selection bias, as well as
over- or under-representation of some months. Includ-
ing both clinical and health care utilization parameters
as enrollment criteria, some of which were subjective,
may have resulted in misclassification bias. Additionally,
we did not obtain samples from healthy control children
without diarrhea for norovirus testing to inform the clin-
ical significance of our results. Finally, the use of more
restrictive primers may have underestimated the overall
burden of norovirus in diarrheal illness in this popula-
tion, and more sensitive, multiplex PCR tests may be
applied to these samples in the future.
A significant difference identified in our study between
norovirus-positive and norovirus-negative illnesses was
latrine type. As oral-fecal contamination is an important
route of transmission for norovirus and other enteric vi-
ruses, sanitation that allows appropriate disposal of feces
may be an important intervention. However, given the
wide variation of latrines prevailing in developing coun-
tries, it remains to be demonstrated whether improved
latrines, such as those connected to a sewer line or with
a lined sub-structure, may be associated with lower risk
of infections such as norovirus.
Conclusions
Norovirus was detected frequently from children < 5 years
of age presenting with diarrhea in our sample derived
from a health facility-based surveillance study. Longitu-
dinal data will be needed to study changes in the relative
Fig. 2 Calendar month of collection and norovirus detection among samples collected from young Zambian children with diarrheal illness
Table 2 Severity score by norovirus genogroup* in young
Zambian children with norovirus-associated diarrheal illness
Genogroup I
(n = 4)
Genogroup II
(n = 10)
p-value
Severity score 1.000
< =10 (mild) 3 (75.0) 8 (80.0)
11–14 (moderate) 1 (25.0) 2 (20.0)
> =15 (severe) 0 (0.0) 0 (0.0)
*Includes data only for subjects in whom severity score was calculable (n = 19)
and genogroup was available (n = 14; one subject excluded due to co-infection
with GI and GII)
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importance of norovirus as a cause of clinically important
diarrhea after widespread rotavirus vaccination implemen-
tation. Our findings and others may inform future strat-
egies to prevent the morbidity and mortality associated
with pediatric diarrheal infections.
Additional file
Additional file 1: Figure S1. Phylogenetic analysis of a 280-bp region of
the partial RNA dependent-RNA polymerase region in norovirus detections
(1A: Genogroup I; 1B: Genogroup II). (PDF 79 kb)
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